98%
921
2 minutes
20
Colorectal cancer (CRC) is one of the most common tumors worldwide, and metastatic CRC is likely to have a poor prognosis. N7-methylguanosine (m7G) is a common methylation modification that is catalyzed primarily by methyltransferase 1 (METTL1). However, the role of m7G in metastatic CRC remains unclear. The role of METTL1 in progressive CRC was initially explored using bioinformatics analysis. Subsequently, its relationship with CRC was further validated through in vitro and in vivo experiments. Potential downstream targets were identified through RNA-seq and quantitative real-time PCR (RT‒qPCR), and the underlying mechanisms were investigated using methylated RNA immunoprecipitation (MeRIP) and RNA degradation assays. Our results revealed that METTL1 is differentially expressed and significantly upregulated in metastatic CRC. This correlation was further confirmed by in vivo and in vitro experiments. RNA sequencing of CRC cells with METTL1 knockdown revealed that intercellular adhesion molecule-1 (ICAM-1) was a significant downstream target and could be stabilized by m7G modification. We revealed that METTL1 is significantly upregulated in metastatic CRC and plays a critical role in CRC progression by stabilizing ICAM-1 through m7G modification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11010-025-05293-0 | DOI Listing |
Biochim Biophys Acta Gen Subj
September 2025
Department of General Surgery, Tianzhu County People's Hospital, Qiandongnan, Guizhou 556699, China.
Colorectal cancer (CRC) remains one of the most lethal malignancies globally, driven by complex molecular mechanisms that contribute to its progression and metastasis. This study focuses on the role of N1-methyladenosine (mA) RNA methylation in CRC, particularly its effect on Rab Interacting Lysosomal Protein-Like 1 (RILPL1) expression and the downstream activation of the CaMKII/CREB signaling pathway. Bioinformatics analysis identified RILPL1 as a key gene associated with poor CRC prognosis, exhibiting increased expression levels in cancerous tissues, with further elevation in metastatic samples.
View Article and Find Full Text PDFBull Cancer
September 2025
Endocrinologie diabétologie et gynécologie pédiatrique, hôpital des Enfants, CHU de Bordeaux, Bordeaux, France.
The harmonization workshops of the leukemia committee of the Société française des cancers de l'enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy.
View Article and Find Full Text PDFESMO Open
September 2025
Aminex Therapeutics, Inc., Kenmore, USA. Electronic address:
Background: Dysregulation of polyamine synthesis has been observed in various cancer cell types. A novel approach to depriving cancer cells of polyamines involves the use of difluoromethylornithine (DFMO) to block polyamine biosynthesis in combination with AMXT 1501, a potent inhibitor of polyamine transport. Preclinical mouse tumor models showed that the combination of AMXT 1501 plus DFMO had strong antitumor activity, together with evidence of a stimulated immune response against tumors.
View Article and Find Full Text PDFCancer Res Commun
September 2025
University of Tsukuba, Tsukuba, Japan.
Immune checkpoint inhibitor (ICI) combinations and tyrosine kinase inhibitor (TKI) use are standard for metastatic renal cell carcinoma (mRCC), leading to improved outcomes. However, due to a lack of predictive biomarkers, the presence or absence of immune-related adverse events (irAEs) is currently employed as a predictive factor in clinical practice. To elucidate the impact of irAEs on efficacy, a cohort of mRCC patients who received ICI-based combination therapy as initial treatment was analyzed.
View Article and Find Full Text PDFDigestive system cancers, including hepatocellular carcinoma (HCC), gastric cancer (GC), pancreatic cancer (PC), and colorectal cancer (CRC), pose a significant global health burden with high morbidity and mortality rates. Their tumorigenesis and progression are driven by complex interactions between genetic alterations and environmental factors. In recent years, long non-coding RNAs (lncRNAs) have emerged as critical regulators in cancer initiation, metastasis, and drug resistance through epigenetic modulation, transcriptional regulation, and post-transcriptional modifications.
View Article and Find Full Text PDF